ErbB targeted drugs and angiogenesis.

Curr Vasc Pharmacol 2010 May;8(3):421-31

Department of Oncology and Radiotherapy, Turku University Central Hospital, FIN-20520 Turku, Finland.

Members of the ErbB receptor tyrosine kinase family are central regulators of several normal as well as tumor cell functions. A number of therapeutic compounds such as small molecular weight tyrosine kinase inhibitors and monoclonal antibodies have been developed to inhibit ErbB signaling in cancer. Drugs that target epidermal growth factor receptor (EGFR = ErbB1) and/or ErbB2 have demonstrated effect against breast, colorectal, lung, pancreatic and head and neck carcinomas, and are currently in clinical use. Part of the anti-tumor effect of the ErbB inhibitor drugs has been suggested to derive from inhibition of tumor angiogenesis. There are several proposed mechanisms by which the ErbB inhibiting agents may regulate tumor neovascularization although most of them are currently not fully characterized. This review addresses the role of ErbB signaling in angiogenesis, as well as the anti-angiogenic mechanisms of ErbB targeted cancer drugs.

Download full-text PDF

Source
http://dx.doi.org/10.2174/157016110791112241DOI Listing
May 2010
15 Reads

Publication Analysis

Top Keywords

cancer drugs
8
erbb signaling
8
tyrosine kinase
8
erbb targeted
8
mechanisms erbb
8
erbb
7
drugs target
4
tumor neovascularization
4
epidermal growth
4
factor receptor
4
growth factor
4
regulate tumor
4
clinical anti-tumor
4
target epidermal
4
signaling cancer
4
currently fully
4
monoclonal antibodies
4
anti-tumor erbb
4
antibodies developed
4
suggested derive
4

Similar Publications